

## **Peter G. Tombros**

Professor and Executive in Residence, Eberly College of Science BS/MBA Program,  
Pennsylvania State University

Former Chairman: NPS Pharmaceuticals

Director: Cambrex

As non-executive chairman of NPS Pharmaceuticals, Peter Tombros played a decisive role in pulling NPS out of a death spiral, tirelessly supporting a compelling but challenging new business model for the company and the new leadership who made it happen.

“Peter’s unwavering conviction through the darkest days, when many thought insolvency was assured, has become reality,” says fellow NPS director Colin Broom.

NPS Pharma suffered a likely mortal blow in 2006 when a potential blockbuster drug – upon which the future of the company hinged – failed to get FDA approval. Mr Tombros embraced management’s bold vision to repurpose the drug portfolio and retool the company to focus on orphan treatments in an effort to lower cost of development and put NPS in a less competitive arena.

“Whether offering coaching during uncertain times, being a wise ear while assessing scenarios or managing board dynamics to keep us aligned, Peter has been a unique partner in building NPS into a global rare disease company,” says Dr Francois Nader, who became CEO of NPS in 2008 as the board embarked upon its new strategy.

The enormous value created for NPS shareholders in the ensuing six years was realized upon the \$5.2 billion sale of NPS to Shire in February 2015. The \$46 per share paid was more than 50% higher than where NPS stock was trading in December 2014. The payoff for people suffering from two rare diseases for which NPS developed new treatments is priceless.

“It took a lot of courage for Peter to support our strategy, as it ran counter to the pharmaceutical industry models of the day. And it has paid off spectacularly,” concludes Dr Nader.

### **Career Highlights**

- Professor and executive in residence, Eberly College of Science BS/MBA Program, Pennsylvania State University (2005 – present)
- Chairman and CEO, VivoQuest (2001 – 2005)
- President, CEO, Enzon Pharmaceuticals (1994 to 2001)
- 25 years with Pfizer in roles including VP of marketing, SVP and GM, Roerig Pharmaceuticals Division, EVP, Pfizer Pharmaceuticals Division
- BS and MS, Pennsylvania State University; MBA, Wharton
- \$2 billion Capital Campaign Chair, Penn State University
- Previous public directorships: Protalex, Inventiv Health Clinical, Cegedim, Icoria